Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 1 6Phase 3 3Phase 1/2 3Phase EARLY_PHASE1 1Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Triple Negative Breast Neoplasms 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Breast Neoplasms 1

Interventions

Paclitaxel 5liposomal doxorubicin 4Topotecan 3Doxorubicin 2Carboplatin 2Bevacizumab 2saracatinib 1pegfilgrastim 1olaparib 1cediranib 1atezolizumab 1Taxes 1Poly(ADP-ribose) Polymerase Inhibitors 1Neoadjuvant Therapy 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Ifosfamide 1Gemcitabine 1Disulfides 1Diathermy 1Chemotherapy, Adjuvant 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Fallopian Tube Neoplasms × olaparib × Clear all
NCT02502266 2026-04-29

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
582 enrolled 21 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡